Alzheimer Disease
📧 Sign up to get email alerts when something new happens for Alzheimer Disease.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2013-03-27FDA Approved: AMYVID — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for AMYVID (florbetapir F 18) from Eli Lilly and Company. The submission status indicates approv…
-
FDA approval · 2013-03-22FDA Approved: AMYVID — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for AMYVID (florbetapir F-18) from Eli Lilly and Company. This action updates the labeling and may e…
-
CLINICAL_TRIALS trial_result · 2013-03-22Clinical Trial Update: Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline [Phase 3]
Phase 3 trial evaluating Florbetapir F 18 PET imaging to inform clinical diagnosis and management in patients with progressive cognitive dec…
-
FDA approval · 2013-03-13FDA Approved: RIVASTIGMINE — Supplemental Application (Sandoz Inc)
FDA approves a supplemental application for rivastigmine submitted by Sandoz Inc.
-
FDA approval · 2013-03-13FDA Approved: AMYVID — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for AMYVID (Florbetapir F-18) from Eli Lilly, advancing its regulatory status for use in evaluating …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2013-03-11FDA Approved: MEMANTINE HYDROCHLORIDE — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for memantine hydrochloride (Actavis Pharma, Inc.), resulting in updated labeling for the produc…
-
EMA withdrawal · 2013-03-11EMA Refused: Acrescent (memantine hydrochloride;donepezil hydrochloride) — H. Lundbeck A/S
EMA refused the Acrescent (memantine hydrochloride; donepezil hydrochloride) application for Alzheimer’s disease.
-
EMA approval · 2013-03-11EMA Refused: Balaxur (memantine hydrochloride;donepezil hydrochloride) — Merz Pharmaceuticals GmbH
EMA decision to refuse Balaxur (memantine hydrochloride; donepezil hydrochloride) for Alzheimer’s disease.
-
FDA approval · 2013-03-06FDA Approved: AMYVID — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for AMYVID (florbetapir F-18) from Eli Lilly and Company.
-
CLINICAL_TRIALS research · 2013-03-06Clinical Trial Update: Multi-modal Neuroimaging in Alzheimer's Disease [NA]
A multi-modal neuroimaging study in Alzheimer's disease is registered, sponsored by University Hospital Caen; the current status is unknown.
-
FDA approval · 2013-02-25FDA Approved: DONEPEZIL HYDROCHLORIDE — Original Application (Alembic Pharmaceuticals Inc.)
FDA approved Alembic Pharmaceuticals Inc.'s original application for donepezil hydrochloride, a generic version of the Alzheimer's disease t…
-
CLINICAL_TRIALS trial_result · 2013-02-22Clinical Trial Update: Memantine and Validation of a New Alzheimer's Disease Scale [Phase 3]
Phase 3 clinical trial of memantine has completed and includes validation of a new Alzheimer's disease assessment scale. The sponsor is Merz…
-
FDA approval · 2013-02-19FDA Approved: AMYVID — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for AMYVID (florbetapir F-18) from Eli Lilly and Company. The notice indicates the agency completed …
-
CLINICAL_TRIALS trial_result · 2013-02-18Clinical Trial Update: The Prevalence of Vitamin D Deficiency in Patients With Alzheimer's Disease
This clinical trial update reports on the prevalence of vitamin D deficiency among patients with Alzheimer's disease based on completed stud…
-
CLINICAL_TRIALS trial_result · 2013-02-11Clinical Trial Update: Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44 [Phase 4]
This report covers a completed Phase 4 trial and its 24-week open-label extension evaluating the rivastigmine transdermal patch in patients …
-
CLINICAL_TRIALS trial_result · 2013-02-08Clinical Trial Update: A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease [Phase 3]
Phase 3 trial update for Dimebon in mild-to-moderate Alzheimer's disease; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2013-02-05Clinical Trial Update: Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease [Phase 3]
Phase 3 trial comparing 23 mg sustained-release donepezil to 10 mg immediate-release donepezil in moderate-to-severe Alzheimer's disease; re…
-
CLINICAL_TRIALS trial_result · 2013-01-31Clinical Trial Update: Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease [Phase 2]
Phase 2 study evaluating efficacy and safety in subjects with mild-to-moderate Alzheimer's disease has completed; the document provides an u…
-
CLINICAL_TRIALS trial_result · 2013-01-31Clinical Trial Update: Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease [Phase 2]
A Phase 2 trial comparing three dosage levels of SAM-531 in outpatients with mild-to-moderate Alzheimer disease was terminated, with results…
-
CLINICAL_TRIALS trial_result · 2013-01-30Clinical Trial Update: To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden [Phase 2]
Phase 2 study sponsored by AstraZeneca compares PET measurements of fibrillar amyloid burden in Alzheimer's disease. The trial status is com…
-
CLINICAL_TRIALS trial_result · 2013-01-29Clinical Trial Update: Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease [Phase 2]
A completed Phase 2 trial evaluated ABT-384 for efficacy and safety in patients with mild-to-moderate Alzheimer's disease.
-
CLINICAL_TRIALS trial_result · 2013-01-25Clinical Trial Update: Use of Different Treatment Care Methods in Patients With Dementia Associated With Alzheimer's Disease
This clinical trial update reports the completion of a study evaluating different treatment care methods for dementia associated with Alzhei…
-
CLINICAL_TRIALS research · 2013-01-25Clinical Trial Update: Memantine on Aggression and Agitation of Alzheimer's Disease (AD) [NA]
This is a clinical trial update for memantine in aggression and agitation associated with Alzheimer's disease. The status is unknown and no …
-
CLINICAL_TRIALS trial_result · 2013-01-21Clinical Trial Update: Evaluation of the Diagnostic Potential of BAY1006578 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of BAY1006578 in Healthy Volunteers [Phase 1]
Phase 1 study evaluating BAY1006578 for diagnostic potential in probable Alzheimer's disease and assessing radiation dosimetry in healthy vo…
-
FDA approval · 2013-01-18FDA Approved: AMYVID — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for AMYVID (florbetapir F-18) from Eli Lilly, updating its labeling. The imaging agent is intended t…